Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
| Autor: | Steve Rozen, Sarah B Ng, William F. Burkholder, Anna Gan, Alexander Y. F. Chung, Kiat Hon Lim, Iain Beehuat Tan, Polly Sy Poon, Matthew C.H. Ng, Su Pin Choo, Clarinda Chua, Patrick Tan, Danliang Ho, Melissa Ching Ching Teo, Cherylin Fu, Wei Qiang Leow, Si-Lin Koo, Mark T. C. Wong |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer Sensitivity and Specificity Article Circulating Tumor DNA Workflow Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Recurrence Internal medicine Multiplex polymerase chain reaction Biomarkers Tumor medicine Humans Neoplasm In patient Postoperative Period Multidisciplinary business.industry Reproducibility of Results Cancer DNA Neoplasm medicine.disease digestive system diseases Treatment Outcome 030104 developmental biology chemistry 030220 oncology & carcinogenesis Mutation Biomarker (medicine) Colorectal Neoplasms business Multiplex Polymerase Chain Reaction DNA |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/srep40737 |
| Popis: | Circulating tumour DNA (ctDNA) has the potential to be a specific biomarker for the monitoring of tumours in patients with colorectal cancer (CRC). Here, our aim was to develop a personalised surveillance strategy to monitor the clinical course of CRC after surgery. We developed patient-specific ctDNA assays based on multiplexed detection of somatic mutations identified from patient primary tumours, and applied them to detect ctDNA in 44 CRC patients, analysing a total of 260 plasma samples. We found that ctDNA detection correlated with clinical events – it is detectable in pre-operative but not post-operative plasma, and also in patients with recurrent CRC. We also detected ctDNA in 11 out of 15 cases at or before clinical or radiological recurrence of CRC, indicating the potential of our assay for early detection of metastasis. We further present data from a patient with multiple primary cancers to demonstrate the specificity of our assays to distinguish between CRC recurrence and a second primary cancer. Our approach can complement current methods for surveillance of CRC by adding an individualised biological component, allowing us not only to point to the presence of residual or recurrent disease, but also attribute it to the original cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|